FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients

September 28, 2022 – September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.

Read More from FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients

FACIT’s David O’Neill shares strategy for Ontario intellectual property

June 16, 2022 – The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.

Read More from FACIT’s David O’Neill shares strategy for Ontario intellectual property

FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics

April 28, 2022 – April 27, 2022 – FACIT announced two recent strategic investments from its Prospects Oncology Fund in innovations arising from renowned cancer experts at the Ontario Institute for Cancer Research (OICR): Dr. Rima Al-awar, Head of Therapeutic Innovation and Drug Discovery, and Dr. Lincoln Stein, Head of Adaptive Oncology.

Read More from FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics

FACIT announces winner of 2022 Falcons’ Fortunes pitch competition on World Cancer Day

February 4, 2022 – February 4, 2022 – FACIT is pleased to announce the 2022 winner of its Falcons’ Fortunes pitch competition: Point Surgical Inc.. Point Surgical was founded as a joint venture between Toronto’s University Health Network, Unity Health Toronto and Light Matter Interaction Inc.

Read More from FACIT announces winner of 2022 Falcons’ Fortunes pitch competition on World Cancer Day

High-potency TIL cell therapy approach reported using CytoFind platform developed by FACIT portfolio company Cellular Analytics

January 27, 2022 – January 27, 2022 – FACIT congratulates portfolio company Cellular Analytics on a recent publication by its CSO, Dr. Shana Kelley and collaborators, on the Company’s tumor-infiltrating lymphocyte (TIL) therapeutics platform.

Read More from High-potency TIL cell therapy approach reported using CytoFind platform developed by FACIT portfolio company Cellular Analytics